Reinforcing the mucus: a new therapeutic approach for ulcerative colitis?
Luminal delivery of phosphatidyl rich phospholipids appears to reduce mucosal inflammatory activity in a high proportion of patients with chronically active ulcerative colitis. The simplicity and apparent safety of this therapeutic approach offers new insights into the importance of the mucus barrier in the pathogenesis and treatment of ulcerative colitis.
Gibson
P R
PR
Monash University, Department of Gastroenterology, Box Hill Hospital, Box Hill, Victoria 3128, Australia. Peter.Gibson@med.monash.edu.au
Muir
J G
JG
D003093:Colitis, Ulcerative / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D009093:Mucus / Q000502:physiology*; D010743:Phospholipids / Q000502:physiology / Q000627:therapeutic use*
D010743:Phospholipids